DanielVirgil ThomasCatenacciMD

PubMed

• 23 citations
  Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.
  Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani
  JCO Precision Oncology. 2022-12-01
• ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Inte...
  Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill
  Annals of Surgical Oncology. 2022-12-01
• 56 citations
  The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
  J E Berchuck, F Facchinetti, D F DiToro, I Baiev, U Majeed
  Annals of Oncology. 2022-12-01

Journal Articles

• Author Correction: Targeting Wild-Type KRAS-Amplified Gastroesophageal Cancer Through Combined MEK and SHP2 Inhibition  
  Daniel Catenacci, Adam J Bass, Shaunt Fereshetian, Rameen Beroukhim, Nature
• The Expansion Platform Type II Design: Testing a Treatment Strategy  
  Catenacci DVT, Lancet Oncology, 1/8/2015
• A randomized pilot phase I study of modified Carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic aden...  
  Geynisman DM, Zha Y, Kunnavakkam R, Aklilu D, Catenacci DVT, Polite BN, Rosenbaum A, Namakydoust A, Karrison T, Gajewski TF, Kindler HL, Journal for ImmunoTherapy of Cancer, 1/1/2013

Books/Book Chapters

• Gastroesophageal Tumors: Principles and Practice. 
  Chapter: Chapter 33: Principles of Multimodality Therapy 
  Page 229 - 242Catenacci DVT, Cohen E., Villaflor VEditors: Jobe, Hunter and Thomas.2009
• Cancer Biology Review: A Case-Based Approach 
  Chapter: Chapter 4: Cell Surface Receptors and Signal Transduction: Principles of Cancer Biology. 
  Catenacci DVTEditors: Stadler and Winters.

Abstracts/Posters

• KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma.
  Henderson L, Xu P, O’Day E, Cecchi F, Blackler A, Liao WL, Hembrough T, Catenacci DVT, GI ASCO 2016, San Francisco, CA, 1/1/2016
• Evaluation of MET as a Prognostic Biomarker Determined by FISH, IHC, or Mass Spectrometry in Patients With Gastroesophageal Cancer.
  Catenacci DVT, Shen J, Liao WL, Oliner KS, Ang A, Loberg R, O’Day E, Xu P, Henderson L, Cecchi F, Burrows J, Hembrough T, Ruzzo A, Graziano F, ECC/ESMO, Vienna, Austria, 1/28/2015
• Her2 expression in Gastroesophageal Cancer (GEC) FFPE Tissue using Mass Spectrometry (MS) and correlation with HER2 gene amplification.
  DVT Catenacci, L Zhao, E Whitcomb, L Henderson, E O'Day, P Xu, SY Xiao, SM Lee, WL Liao, SP Thyparambil, J Uzzell, M Darfler, D Krizman, J Burrows, TA Hembrough, ASCO GI, San Francisco, CA, 1/1/2015
• Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations.
  JS Ross, K Wang, DVT Catenacci, J Chmielecki, SM. Ali, JA Elvin, R Yelensky, D Lipson, MJ Hawryluk, VA Miller, PJ Stephens, MM Javle, ASCO GI, San Francisco, CA, 1/1/2015
• A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
  JC Bendell, H Hochster, LL Hart, I Firdaus, JR Mace, JJ McFarlane, M Kozloff, D Catenacci, J Hsu, S Hack, D Shames, S Phan, AL Cohn, ASCO GI, San Francisco, CA, 1/1/2015
• Clinical activity of AMG 337, a highly selective oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), o...
  E. L. Kwak, P. LoRusso, O. Hamid, F. Janku, M. Kittaneh, D Catenacci, E. Chan, T. Bekaii-Saab, B. Amore, Y. Hwang, R. Tang, G. Ngarmchamnanrith, D. Hong, ASCO GI, San Francisco, CA, 1/1/2015
• Relationship Between PD-L1 Expression and Clinical Outcomes in Patients (Pts) With Advanced Gastric Cancer Treated With the Anti-PD-1 Monoclonal Antibody Pembrolizumab...
  K Muro, YJ Bang, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, R Berger, EJ Gonzalez, J Pulini, A Ray, M Dolled-Filhart, K Emancipator, K Kort, K Pathiraja, X Sh..., ASCO GI, San Francisco, CA, 1/1/2015
• FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).
  AC Lockhart, K Krajewski, A Wang-Gillam, M Amin, S Sorscher, K Lim, B Tan, J Picus, A Hecky, K Allen, JD Peterson, E O’Day, RdW Marsh, M Kozloff, BN Polite, HL Kindler..., ASCO GI, San Francisco, CA, 1/1/2015
• Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for immunooncology targets in FFPE Samples.
  E An; WL Liao; S Thyparambil; J Rodriguez; R Salgia; II Wistuba; J Burrows; T Hembrough; DVT Catenacci, AACR, Philadelphia, PA, 1/1/2015
• Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.
  Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Meric-Bernstam, J Clin Oncol; ASCO, Chicago, IL, 1/1/2015
• MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC).
  Catenacci DVT, Tang R, Oliner K, Ang A, Loberg RD, OE, Xu P, Henderson L, Ruzzo A, Graziano F, J Clin Oncol; ASCO, Chicago, IL, 1/1/2015
• Correlation of Gene Expression Signatures and Clinical Outcomes in Patients With Advanced Gastric Cancer Treated With Pembrolizumab (MK-3475).
  Shankaran V, Muro K, Bang YJ, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Loboda A, Albright A, Cristescu R, Murphy E, McClanahan T, Ayers M, Nebozhyn M, Luncef..., ASCO, Chicago, IL, 1/1/2015
• Phase 3, randomized, double-blind, multicenter, placebo-controlled trial of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in...
  Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani M, Udrea AA, Baker N, Oliner KS, Z..., ASCO, Chicago, IL, 1/1/2015
• Challenges of applying tumor genome analysis to the germline: Examples from GI Oncology.
  Amico A, Nielsen S, Geynisman D, Rambo B, Carey GB, Gulden C, Facekenthal J, Olopade O, Catenacci D, AACR Cancer Susceptibility and Cancer Susceptibility Syndromes Conference, San Diego, CA, 1/29/2014
• Phase Ib Study of Pembrolizumab (Pembro; MK-3475) in Patients (Pts) With Gastric Cancer.
  K Muro, YJ Bang, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, R Berger, EJ Gonzalez, J Pulini, A Ray, M Dolled-Filhart, K Emancipator, K Kort, K Pathiraja, X Sh..., ESMO, Madrid, Spain, 1/24/2014
• KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined antiRAS/RAF/MEK/ERK and PIK3/PTEN/mTOR...
  Henderson L, Peng Xu, Rambo B, Liao WL, J, Hembrough T, Catenacci DVT, AACR KRAS, Orlando, FL, 1/21/2014
• Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS).
  Hembrough T, Henderson L, Rambo B, Liao WL, Thyparambil S, Bengali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao SY, Zhao L, Burrows J, Catenacci DVT, J Clin Oncol, San Francisco, CA, 1/16/2014
• Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue.
  Hembrough T, Liao WL, Henderson L, Rambo B, Thyparambil S, Cecchi F, Bottaro D, Bengali K, Uzzell J, Darfler M, Xu P, Xiao SY, Zhao L, Krizman D, Veenstra T, Burrows J..., J Clin Oncol, San Francisco, CA, 1/16/2014
• Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity – PANGEA.
  Catenacci DVT, Polite B, Henderson L, Peng Xu, Rambo B, Liao WL, Hembrough T, Burrows J, Zhao L, Hart J, Xiao SY, Karrison T, Dignam J, Kindler HL, J Clin Oncol, San Francisco, CA, 1/16/2014
• Kinase activity profiling combined with genotyping as a tool for predictive biomarker discovery for the treatment of gastroesophageal adenocarcinoma (GEC).
  Catenacci DVT, Xu P, Henderson L, Pijnenburg D, van den Berg A, Ruijtenbeek R, AACR Annual Meeting, San Diego, CA, 1/5/2014
• Detection of Portal Vein (PV) Circulating Tumor Cells (CTCs) in Pancreatic Cancer (PC) patients obtained by EUS guided PV Sampling. A safety and Feasibility trial.
  Waxman I, Chapman C, Koons A, Konda V, Siddiqui U, Gelrud A, Xu P, Catenacci DVT, Digestive Disease Week, Chicago, IL, 1/4/2014
• A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
  Sharma MR, Catenacci DVT, Karrison TG, Marsh RW, Kozloff M, Allen K, Polite BN, Kindler HL, ASCO, 1/1/2014
• Absolute quantitation of MET using mass spectrometry for clinical application: assayprecision, stability, and correlation with met gene amplification in FFPE tumor tis...
  T Hembrough, L Henderson, B Rambo, WL Liao, S Thyparambil, K Bengali, J Uzzell, M Darfler, D Krizman, P Xu, S-Y Xiao, L Zhao, J Burrows, DV Catenacci, EORTC, Barcelona, Spain, 1/1/2014
• Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS).
  T Hembrough, L Henderson, B Rambo, WL Liao, S Thyparambil, K Bengali, J Uzzell, M Darfler, D Krizman, P Xu, S-Y Xiao, L Zhao, J Burrows, DV Catenacci, EORTC, Barcelona, Spain, 1/1/2014
• A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal jun...
  Cohen DJ, Christos PJ, Sparano JA, Catenacci DVT, Kindler HL, Bekaii-Saab TB, Tahiri S, Yuriy Y, Givson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandri..., GI ASCO, San Francisco, CA, 1/24/2013
• Join now to see all

Lectures

• Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophagea... 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
• Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289). 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
• Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA). 
  2019 ASCO Annual Meeting - 6/1/2019
• FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untre... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• General Session 3: Multimodal Approaches for Advanced GE Junction Cancers (East and West)--Challenging Cases” (Session Chair) 
  ASCO GI, San Francisco, CA - 1/21/2016
• "Tumor molecular heterogeneity, molecular evolution, and implications in the clinic". 
  UCCCC Translational Seminars - 1/12/2016
• "Next-Generation Clinical Trials Incorporating Next-Generation Companion Diagnostics". 
  OMICS 2nd Annual Meeting, Patrick Soon-Shiong NantOmics. Los Angeles, CA - 1/30/2015
• “Tumor Board: Management of Challenging Cases of Upper Gastrointestinal Cancers (ARS)" (Invited Panelist) 
  ASCO GI, San Francisco, CA - 1/15/2015
• “Does Molecular Profiling Predict Response to Therapy?” 
  Hepatic Tumor Summit, Tampa, FL - 1/14/2015
• “Tumors to the Liver: Metastatic Adenocarcinoma of Unknown Origin – Work up before Therapy and Role of Molecular Profiling to Sort it out” 
  Hepatic Tumor Summit, Tampa, FL - 1/14/2015
• "Tumor Genomics, Immunotherapy, Clinical Trials, and Other Hopes for the Future.” (Committee Chair and Organizer, Moderator, Speaker) 
  Debbie’s Dream Foundation for Stomach Cancer Inaugural Chicago Symposium, O’Hare Marriot, Chicago, I - 1/7/2015
• “Analyzing Your Genome”. 
  Rolfe Foundation Symposium on Personalized Medicine, Cancer Wellness Center, Northbrook, IL - 1/5/2015
• "Strategies to address inter- and intra- patient tumor molecular heterogeneity using nextgeneration companion diagnostics and PANGEA: a novel clinical trial design". 
  Grand Rounds University of California San Diego, CA - 1/3/2015
• “Meeting Highlights: Gastrointestinal Cancer.” 
  ASCO Trainee & Early-Career Oncologist Lounge. ASCO 2015, Chicago IL. - 1/1/2015
• "Strategies to address inter- and intra- patient tumor molecular heterogeneity using next-generation companion diagnostics and PANGEA: a novel clinical trial design". 
  Nantworks/NantHealth, Los Angeles, CA - 1/24/2014
• “Personalized Colon Cancer Care: Are we there yet?“ 
  University of Chicago Symposium, The Board of Regents Room, American College of Surgeons, North St. - 1/10/2014
• Detection of Portal Vein (PV) Circulating Tumor Cells (CTCs) in Pancreatic Cancer (PC) patients obtained by EUS guided PV Sampling. A safety and Feasibility trial. 
  Digestive Disease Week, Chicago, IL - 1/1/2014
• “MET Tyrosine Kinase and GI Cancers.” 
  University of Chicago Department of Medicine Section of Hematology/Oncology AbbVie Meeting KCBD, Chi - 1/25/2013
• Invited Panelist for the Foundation One Virtual Tumor Board. Case Presentation of Cholangiocarcinoma and Discussion. 
  1/25/2013
• “Gastroesophageal Adenocarcinoma in The Era of Targeted Therapies: A Focus on MET” 
  Amgen Oncology Global Advisory Board. Thousand Oaks, CA - 1/20/2013
• “Treatment of Advanced Gastroesophageal Cancer: A Focus on Targeted Therapies” - JACOB phase III Clinical Trial Investigators’ Meeting: A double-blind, placebo-control... 
  International Investigator Meeting. InterContinental, Chicago, IL - 1/18/2013
• “Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneity…PANGEA." 
  The University of Chicago Phase II Consortium 18th Annual Symposium, Gleacher Center, Chicago - 1/12/2013
• “Current trends in Colon Cancer Therapy: agents and approach” 
  Cancer Biology 1: Human Cancer Presentation and Modeling - 1/31/2012
• “Pancreatic Cancer: Hedgehog Signaling & the new era of FOLFIRINOX”. 
  The University of Chicago Phase II Consortium 17th Annual Symposium, Gleacher Center, Chicago, IL - 1/27/2012
• Join now to see all